Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Rubin

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Gynecologic Oncology|September 28, 2011
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerSarah F Adams, Evelyn B Marsh, Wafic Elmasri, et al.
Cancer|May 28, 2009
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancerSarah F Adams, Douglas A Levine, Mark G Cadungog, et al.
Gynecologic Oncology|August 29, 2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyCarol Aghajanian, John A Blessing, Kathleen M Darcy, et al.
Gynecologic Oncology|October 13, 2010
Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entityJohn B Liao, Stephanie Jean, Ivy Wilkinson-Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Jose-Ramon Conejo-Garcia, et al.
Gynecologic Oncology|July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
American Journal of Epidemiology|September 26, 2006
Case-control study of postmenopausal hormone replacement therapy and endometrial cancerBrian L Strom, Rita Schinnar, Anita L Weber, et al.
Cancer Research|July 23, 2003
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Dionyssios Katsaros, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group studyKrishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Gynecologic Oncology|September 28, 2011
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerSarah F Adams, Evelyn B Marsh, Wafic Elmasri, et al.
Cancer|May 28, 2009
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancerSarah F Adams, Douglas A Levine, Mark G Cadungog, et al.
Gynecologic Oncology|August 29, 2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyCarol Aghajanian, John A Blessing, Kathleen M Darcy, et al.
Gynecologic Oncology|October 13, 2010
Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entityJohn B Liao, Stephanie Jean, Ivy Wilkinson-Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Jose-Ramon Conejo-Garcia, et al.
Gynecologic Oncology|July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
American Journal of Epidemiology|September 26, 2006
Case-control study of postmenopausal hormone replacement therapy and endometrial cancerBrian L Strom, Rita Schinnar, Anita L Weber, et al.
Cancer Research|July 23, 2003
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Dionyssios Katsaros, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group studyKrishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
Pageof 6